A Phase-II Study with Idarubicin, Ifosfamide and VP-16 (IIVP-16) in Patients with Refractory or Relapsed Aggressive and High Grade non-Hodgkin's Lymphoma

A. Engert Klinik I fñ Innere Medizin, Universität zu KÖln, KÖln, Joseph-Stelzmann-Strab˜e 9, D-50924, KÖln, GÖttingen, Germany

R. Schnell Klinik I fñ Innere Medizin, Universität zu KÖln, KÖln, Joseph-Stelzmann-Strab˜e 9, D-50924, KÖln, GÖttingen, Germany

F. Kñpper Klinik I fñ Innere Medizin, Universität zu KÖln, KÖln, Joseph-Stelzmann-Strab˜e 9, D-50924, KÖln, GÖttingen, Germany

M. Reiser Klinik I fñ Innere Medizin, Universität zu KÖln, KÖln, Joseph-Stelzmann-Strab˜e 9, D-50924, KÖln, GÖttingen, Germany

M. Engelhard Medizinische Klinik, Universitätsklinikum Essen, Essen, GÖttingen, Germany

M. Wilhelm Universitätsklinik Wñrzburg, Medizinische Poliklinik, Wñrzburg, GÖttingen, Germany

B. Lathan Klinik I fñ Innere Medizin, Universität zu KÖln, KÖln, Joseph-Stelzmann-Strab˜e 9, D-50924, KÖln, GÖttingen, Germany

S. Baltes-Engler Pharmacia/Farmitalia, Freiburg, GÖttingen, Germany

B. Winterhalter Pharmacia/Farmitalia, Freiburg, GÖttingen, Germany

M. E. Scheulen Innere Klinik, Tumorforschung, Universitätsklinikum Essen, Essen, GÖttingen, Germany

B. Dederichs Klinik und Poliklinik fñr Nuklearmedizin, Universitat zu KÖln, KÖln, GÖttingen, Germany

H. Tesch Klinik I fñ Innere Medizin, Universität zu KÖln, KÖln, Joseph-Stelzmann-Strab˜e 9, D-50924, KÖln, GÖttingen, Germany

B. Wörmann Med. Universitätsklinik GÖttingen, Zentrum fñr Innere Medizin, GÖttingen, Germany

V. Diehl Klinik I fñ Innere Medizin, Universität zu KÖln, KÖln, Joseph-Stelzmann-Strab˜e 9, D-50924, KÖln, GÖttingen, Germany

show all

Abstract

We report a phase-II study of idarubicin, ifosphamide and etoposide (IIVP-16) in heavily pretreated patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. The IIVP-16 regimen consisted of idarubicin (10mg/m² i.v. days 1 + 2 or days 1 + 8), ifosfamide (1000mg/m² i.v. days 1-5) and VP-16 (150mg/m^{2< 0.025}), Leukopenia and thrombocytopenia were the major toxicities occurring in 73/107 (68.2%) and 57/107 (53.3%) of cycles (WHO grade IV). IIVP-16 is an effective regimen particularly in patients with unfavorable relapsed NHL.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A Phase-II Study with Idarubicin, Ifosfamide and VP-16 (IIVP-16) in Patients with Refractory or Relapsed Aggressive and High Grade non-Hodgkin's Lymphoma

Information for

Open access

Opportunities

Help and information

A Phase-II Study with Idarubicin, Ifosfamide and VP-16 (IIVP-16) in Patients with Refractory or Relapsed Aggressive and High Grade non-Hodgkin's Lymphoma

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature